Pendergraft WF, Nachman PH. Recent pathogenetic advances in ANCA-associated vasculitis. Presse Med. 2015;44(6 Pt 2):e223-9. doi:10.1016/j.lpm.2015.04.007
Walpita D, Wagner BK. Evaluation of compounds in primary human islet cell culture. Curr Protoc Chem Biol. 2014;6(3):157-68. doi:10.1002/9780470559277.ch140088
Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53. doi:10.1038/nm.2307
Mani DR, Abbatiello SE, Carr SA. Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics. BMC Bioinformatics. 2012;13 Suppl 16:S9. doi:10.1186/1471-2105-13-S16-S9
Spracklen CN, Saftlas AF, Triche EW, et al. Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. Am J Hypertens. 2015;28(7):915-23. doi:10.1093/ajh/hpu242
Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clin Immunol. 2015;161(1):51-8. doi:10.1016/j.clim.2015.06.015
Shaham O, Slate NG, Goldberger O, et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci U S A. 2010;107(4):1571-5. doi:10.1073/pnas.0906039107
Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013;10(1):28-34. doi:10.1038/nmeth.2309
Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131(9):774-85. doi:10.1161/CIRCULATIONAHA.114.013116
Kroksveen AC, Jaffe JD, Aasebø E, et al. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 2015;15(19):3361-9. doi:10.1002/pmic.201400142